Skip to main content
Login
Contact
Subscribe
ShopMarshallCountyOnline
Search form
Search
The Pilot News
Home
Forms
News
The Leader of Starke County
Culver Citizen
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Entertainment
Calendar
Friends To Follow
Special Sections
Talking About...
Photos
Videos
Games
Local Guide
Local Ads
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Medicinova Inc
(NQ:
MNOV
)
8.640
USD
+0.190 (+2.25%)
Official Closing Price
/ Updated:
5:16 PM EST, Feb 22, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
41,400
Open
8.550
Bid (Size)
6.750 (3)
Ask (Size)
9.100 (1)
Prev. Close
8.450
Today's Range
8.380 - 8.670
52wk Range
6.680 - 14.50
Shares Outstanding
41,129,073
Dividend Yield
N/A
Performance
YTD
+5.37%
+5.37%
1 Month
-2.26%
-2.26%
3 Month
-9.72%
-9.72%
6 Month
-18.03%
-18.03%
1 Year
-18.64%
-18.64%
Top News
More News
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative
January 21, 2019
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received...
Read More
from
GlobeNewswire News Releases
MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma
January 08, 2019
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first...
Read More
from
GlobeNewswire News Releases
More News
Read More
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
January 07, 2019
from
GlobeNewswire News Releases
MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco
December 12, 2018
from
GlobeNewswire News Releases
MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
October 04, 2018
from
GlobeNewswire News Releases
MNOV Makes Bullish Cross Above Critical Moving Average
January 17, 2019
category
Stocks
from
Market News Video
Relative Strength Alert For Medicinova
December 20, 2018
category
Stocks
from
Market News Video
Analysts Anticipate 25% Gains Ahead For IEIH
November 20, 2018
category
ETFs
from
ETF Channel
Commit To Buy Medicinova At $7.50, Earn 17.4% Annualized Using Options
October 18, 2018
category
Stocks
from
Market News Video
We Did The Math IEIH Can Go To $32
October 16, 2018
category
ETFs
from
ETF Channel
71 Biggest Movers From Yesterday
February 20, 2019
category
INVE
,
PCMI
,
SBGL
, and 82 more.
from
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
